JAMA ophthalmologyPub Date : 2025-04-01DOI: 10.1001/jamaophthalmol.2025.0111
Bryanna Lee, Jennifer Bu, Nathan Scott
{"title":"Conjunctival Nodule in a Female With Ulcerative Colitis.","authors":"Bryanna Lee, Jennifer Bu, Nathan Scott","doi":"10.1001/jamaophthalmol.2025.0111","DOIUrl":"10.1001/jamaophthalmol.2025.0111","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"356-357"},"PeriodicalIF":7.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA ophthalmologyPub Date : 2025-04-01DOI: 10.1001/jamaophthalmol.2024.6113
David B Warner, Bennie H Jeng, Jiyu Kim, Mengling Liu, Andrea B Troxel, Judith S Hochman, Keith H Baratz, Shahzad I Mian, Mazen Y Choulakian, Jay J Meyer, Ying Lu, Alberta Twi-Yeboah, Ting-Fang Lee, Carlos Lopez-Jimenez, Sarah C Laury, Elisabeth J Cohen
{"title":"Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial.","authors":"David B Warner, Bennie H Jeng, Jiyu Kim, Mengling Liu, Andrea B Troxel, Judith S Hochman, Keith H Baratz, Shahzad I Mian, Mazen Y Choulakian, Jay J Meyer, Ying Lu, Alberta Twi-Yeboah, Ting-Fang Lee, Carlos Lopez-Jimenez, Sarah C Laury, Elisabeth J Cohen","doi":"10.1001/jamaophthalmol.2024.6113","DOIUrl":"10.1001/jamaophthalmol.2024.6113","url":null,"abstract":"<p><strong>Importance: </strong>Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care.</p><p><strong>Objective: </strong>To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO).</p><p><strong>Design, setting, and participants: </strong>Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months.</p><p><strong>Intervention: </strong>Treatment with 1000 mg/d of valacyclovir or placebo for 12 months.</p><p><strong>Main outcomes and measures: </strong>Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication.</p><p><strong>Results: </strong>Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (<60 years or ≥60 years) and disease duration (recent [<6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, -20.8% to 25.8%]; P>.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months (P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, -3.39 months [95% CI, -6.73 to -0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01).</p><p><strong>Conclusions and relevance: </strong>O","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"277-285"},"PeriodicalIF":7.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA ophthalmologyPub Date : 2025-04-01DOI: 10.1001/jamaophthalmol.2024.6489
Olivia J Killeen, Leona Ding, Laura Enyedi, Grace Sun, Michelle T Cabrera
{"title":"Sexual Harassment in Ophthalmology.","authors":"Olivia J Killeen, Leona Ding, Laura Enyedi, Grace Sun, Michelle T Cabrera","doi":"10.1001/jamaophthalmol.2024.6489","DOIUrl":"10.1001/jamaophthalmol.2024.6489","url":null,"abstract":"<p><strong>Importance: </strong>High rates of sexual harassment were reported among ophthalmologists who responded to a survey in 2018. A comparison with the rates in 2023 seems warranted following increased initiatives to combat sexual harassment.</p><p><strong>Objectives: </strong>To compare the rates and characteristics of sexual harassment in ophthalmology from survey respondents in 2018 and 2023 and to investigate rates of gender discrimination among the 2023 respondents.</p><p><strong>Design, setting, and participants: </strong>In this cross-sectional, observational survey study, the survey was administered anonymously using Google Forms through the Women in Ophthalmology email blast list from August 25 to September 25, 2023. Primarily female ophthalmologists or ophthalmology trainees were surveyed in the United States and Canada. The study was determined to be exempt by the University of Washington institutional review board because it involved an anonymous, low-risk survey of adults. Participants provided consent electronically.</p><p><strong>Main outcomes and measures: </strong>Rates of sexual harassment in ophthalmology, number of occurrences in the past 5 years, and gender discrimination. Rates were compared between the 2018 and 2023 surveys.</p><p><strong>Results: </strong>Of 1051 emails sent, 692 (65.8%) were opened, and of those opened, 289 of 692 eligible participants (41.8%) responded, so that the respondents represented 289 (27.5%) of the 1051 emails sent. Among the 288 survey participants who provided gender data, there were 282 women (97.9%), 3 men (1.0%), 1 nonbinary or third gender participant (0.3%), and 2 other participants (ie, they preferred not to say or preferred to self-describe) (0.6%), with 113 (39.2%) aged 31 to 40 years. Of the 289 survey respondents in 2023, 172 (59.5%) experienced sexual harassment in ophthalmology compared with 265 of 447 (59.3%) surveyed in 2018 (difference, 0.2%; 95% CI, -7.0% to 7.5%; P = .95). Also, of the 172 respondents in 2023 who reported experiencing sexual harassment, 107 (62.2%) experienced it within the past 5 years compared with 125 of 265 respondents (47.2%) who reported experiencing it in 2018 (difference, 15.0%; 95% CI, 5.5%-24.2%; P < .001). In 2023, 41 of 170 respondents (24.1%) reported their most severe experience to an authority compared with 40 of 265 (15.1%) in 2018 (difference, 9.0%; 95% CI, 1.3%-16.8%; P = .02). Of 287 survey respondents in 2023, 244 (85.0%) experienced gender discrimination.</p><p><strong>Conclusions and relevance: </strong>In this survey study, the rates of sexual harassment among respondents remained high 5 years after a survey on sexual harassment in ophthalmology, with higher frequency of recent experiences and continued low reporting rates. With other forms of gender discrimination also highly prevalent among respondents, these results support pursuit of validated strategies to foster a culture of zero tolerance toward harassment and discrimination","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"348-353"},"PeriodicalIF":7.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA ophthalmologyPub Date : 2025-04-01DOI: 10.1001/jamaophthalmol.2025.0214
Jonah E Yousif, Mark W Johnson
{"title":"Presumed Pentosan Polysulfate Maculopathy With Limited Drug Exposure.","authors":"Jonah E Yousif, Mark W Johnson","doi":"10.1001/jamaophthalmol.2025.0214","DOIUrl":"10.1001/jamaophthalmol.2025.0214","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"362-363"},"PeriodicalIF":7.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA ophthalmologyPub Date : 2025-04-01DOI: 10.1001/jamaophthalmol.2024.6491
Julia A Haller
{"title":"#MeToo in Ophthalmology.","authors":"Julia A Haller","doi":"10.1001/jamaophthalmol.2024.6491","DOIUrl":"10.1001/jamaophthalmol.2024.6491","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"354-355"},"PeriodicalIF":7.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA ophthalmologyPub Date : 2025-03-20DOI: 10.1001/jamaophthalmol.2024.5708
Kundian Guo, Chunxia Jiang, Zhen Hong
{"title":"Intraventricular Silicone Oil After Retinal Detachment Repair","authors":"Kundian Guo, Chunxia Jiang, Zhen Hong","doi":"10.1001/jamaophthalmol.2024.5708","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.5708","url":null,"abstract":"This case report discusses a diagnosis of intraventricular silicone oil discovered 2 years after silicone oil tamponade was performed for retinal detachment repair for proliferative diabetic retinopathy in a woman aged 54 years.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"29 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA ophthalmologyPub Date : 2025-03-20DOI: 10.1001/jamaophthalmol.2024.6230
Enrique J. González-Coín, Ester Carreño
{"title":"Depigmentation of RPE Hypertrophy in Vogt-Koyanagi-Harada Syndrome","authors":"Enrique J. González-Coín, Ester Carreño","doi":"10.1001/jamaophthalmol.2024.6230","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.6230","url":null,"abstract":"This case report discusses the depigmentation of retinal pigment epithelium (RPE) hypertrophy in a patient with Vogt-Koyanagi-Harada syndrome receiving high-dose corticosteroid treatment.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"92 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}